Semaglutide’s Impact on Appetite and Satiety in Obese American Males: An fMRI Study
Reading Time: 3 minutesIntroduction The prevalence of obesity and related metabolic disorders continues to rise, prompting the need for effective therapeutic interventions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising treatment for obesity due to its ability to reduce appetite and enhance satiety. This article delves into a comprehensive study that utilized functional magnetic resonance imaging (fMRI) to explore... Read more »